GLP-1 Drugs Could Lower US Mortality by 6.4% by 2045

Swiss Re's latest research suggests GLP-1 weight-loss drugs could potentially reduce cumulative all-cause mortality by 6.4% in the US by 2045. In the UK, a 5.1% reduction is projected. This optimistic outlook hinges on the widespread availability and adoption of these medications, along with lifestyle and nutritional changes.

The US, with an obesity rate of over 40% among adults, stands to benefit significantly, as does the UK with its 30% obesity rate. Rising obesity has stalled life expectancy in developed markets, with obesity linked to major causes of death such as heart disease and certain cancers.

Swiss Re notes that for the full potential of GLP-1 drugs to be realized, people must adopt healthier lifestyles and adhere to treatments. A pessimistic scenario predicts only modest mortality reductions if uptake is limited and lifestyle changes are not embraced.